OS Therapies Q1 net op loss $3.876M; OST-HER2 BLA on track for Q3 2025

OS Therapies Inc

2025-Q1 EPS reported -$0.18 vs consensus -$0.08 ▼ miss (-120.6%)

Net operating loss of $3.876M in Q1 2025 vs $1.490M in Q1 2024, due to trial closeout and regulatory prep costs.
Net loss per share of $0.18 on 21.249M shares vs $0.25 on 5.991M shares in prior year period.
Positive Phase 2b data for OST-HER2 in pediatric osteosarcoma; FDA Type D meeting feedback expected mid-June 2025.
Company on track to file BLA for OST-HER2 in Q3 2025 for accelerated approval in osteosarcoma.
Acquired three clinical-stage and eight preclinical listeria immunotherapy assets from Ayala Pharmaceuticals.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.